Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHTG8P)

Drug Name

TP-0903 Drug Info

Synonyms

YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 56839178
CAS Number: CAS 1341200-45-0
TTD Drug ID: DMHTG8P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[2]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[3]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[4]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[5]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[6]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[7]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[2]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[8]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03572634) Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Company report (Mirati Therapeutics: formerly MethylGene)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
7	Clinical pipeline report, company report or official report of BioAtla
8	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
9	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
10	National Cancer Institute Drug Dictionary (drug name RXDX106).